GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Total Equity

SELLAS Life Sciences Group (FRA:RXK3) Total Equity : €8.91 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Total Equity?

SELLAS Life Sciences Group's total equity for the quarter that ended in Mar. 2024 was €8.91 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

SELLAS Life Sciences Group Total Equity Historical Data

The historical data trend for SELLAS Life Sciences Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Total Equity Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.48 22.98 18.01 4.58 -7.31

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.30 4.47 -3.59 -7.31 8.91

SELLAS Life Sciences Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

SELLAS Life Sciences Group's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=5.703-13.017
=-7.31

SELLAS Life Sciences Group's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=22.479-13.57
=8.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group Total Equity Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SELLAS Life Sciences Group (FRA:RXK3) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Total Equity
Comparable Companies
LGVN CLRB SKYE FIXX UBX SYBX VYNE PRTG NXTC ELAB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
SLS:USA
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
Website
https://www.sellaslifesciences.com
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines